MediWound Ltd. (MDWD)

NGM – Real Time Price. Currency in USD

15.19

+0.60 (4.11%)

At close: Jun 26, 2026, 4:00 PM EDT

15.19

0.00 (0.00%)

After-hours: Jun 26, 2026, 4:31 PM EDT

27.05.2026

MediWound Ltd. (MDWD) Q1 2026 Earnings Call Transcript

27.05.2026

MediWound Q1 Earnings Call Highlights

MediWound NASDAQ: MDWD reported a wider first-quarter loss and lower revenue compared with the prior-year period, while management reaffirmed its 2026 revenue outlook and said it continued to advance its EscharEx and NexoBrid programs.

27.05.2026

MediWound (MDWD) Reports Q1 Loss, Misses Revenue Estimates

MediWound (MDWD) came out with a quarterly loss of $0.23 per share versus the Zacks Consensus Estimate of a loss of $0.65. This compares to a loss of $0.07 per share a year ago.

27.05.2026

MediWound Reports First Quarter 2026 Financial Results and Provides Corporate Update

EscharEx ® Phase III VALUE trial advancing; interim assessment and enrollment completion expected by the end of the first quarter of 2027 First quarter revenue of $1.5 million; full-year 2026 revenue guidance reaffirmed at $24-26 million Conference Call Today, May 27, 2026, at 8:30 a.m. Eastern Time YAVNE, Israel, May 27, 2026 (GLOBE NEWSWIRE) -- MediWound Ltd.

07.05.2026

MediWound to Report First Quarter 2026 Financial Results

MediWound to Report First Quarter 2026 Financial Results Conference Call and Webcast Scheduled for Wednesday, May 27 th at 8:30 a.m. Eastern Time YAVNE, Israel, May 7, 2026 -- MediWound Ltd.

13.04.2026

Newly Published U.S. Expert Consensus Aligns with MediWound's Strategy for Chronic Wound Debridement

Newly Published U.S. Expert Consensus Aligns with MediWound's Strategy for Chronic Wound Debridement Peer-reviewed consensus redefines debridement from simple tissue removal to a more comprehensive biologically active driver of wound healing Panel supports early use of effective, less invasive treatments in chronic wound care, reinforcing the commercial thesis for EscharEx ® in chronic wound care YAVNE, Israel, April 13, 2026 — MediWound Ltd. (Nasdaq: MDWD), a global leader in next-generation enzymatic therapeutics for tissue repair, today highlighted the publication of a peer-reviewed supplement in WOUNDS titled “Toward a Practical Framework for Debridement in Chronic Wounds: Findings From a United States-Based Multidisciplinary Consensus Panel.

07.04.2026

MediWound to Present New EscharEx® Data at Leading Wound Care Conferences

MediWound to Present New EscharEx ® Data at Leading Wound Care Conferences Data highlights mechanism of action, outcomes in VLUs and DFUs, and comparative advantages over SANTYL ® Findings support ongoing VALUE Phase III study and planned expansion into DFUs and pressure ulcers YAVNE, Israel, April 7, 2026 (GLOBE NEWSWIRE) — MediWound Ltd. (Nasdaq: MDWD), a global leader in next-generation enzymatic therapeutics for tissue repair, today announced multiple oral and poster presentations at three leading wound care conferences: the Wound Healing Society (WHS) and the Symposium on Advanced Wound Care (SAWC) Spring 2026, taking place April 8–12 in Charlotte, North Carolina, and the European Wound Management Association (EWMA) 2026, taking place May 6–8 in Bremen, Germany.

Videos

No Data

There is no data to display

Press releases

27.05.2026

MediWound Reports First Quarter 2026 Financial Results and Provides Corporate Update

13.04.2026

Newly Published U.S. Expert Consensus Aligns with MediWound's Strategy for Chronic Wound Debridement

02.04.2026

MediWound Reports BARDA Contract Award to Vericel for NexoBrid® Valued at up to $197 Million

MediWound Reports BARDA Contract Award to Vericel for NexoBrid ® Valued at up to $197 Million YAVNE, Israel, April 2, 2026 — MediWound Ltd. (Nasdaq: MDWD), a global leader in next-generation enzymatic therapeutics focused on non-surgical tissue repair, today announced that Vericel Corporation (NASDAQ:VCEL), its exclusive distributor of NexoBrid® in North America, has been awarded a ten-year contract valued at up to $197 million by the U.S. Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) within the U.S. Department of Health and Human Services (HHS).

05.03.2026

MediWound Files Annual Report on Form 20-F

MediWound Files Annual Report on Form 20-F YAVNE, Israel, March 5 , 202 6 -- MediWound Ltd. (Nasdaq: MDWD), a global leader in next-generation enzymatic therapeutics for tissue repair, t oday announced that it has filed its annual report on Form 20-F for the fiscal year ended December 31, 2025 with the U.S. Securities and Exchange Commission (the “SEC”) on March 5, 2026.

MediWound Ltd. (MDWD)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

MediWound Ltd. (MDWD)

MediWound Ltd. (MDWD) Q1 2026 Earnings Call Transcript

MediWound Q1 Earnings Call Highlights

MediWound (MDWD) Reports Q1 Loss, Misses Revenue Estimates

MediWound Reports First Quarter 2026 Financial Results and Provides Corporate Update

MediWound to Report First Quarter 2026 Financial Results

Newly Published U.S. Expert Consensus Aligns with MediWound's Strategy for Chronic Wound Debridement

MediWound to Present New EscharEx® Data at Leading Wound Care Conferences

Videos

No Data

Press releases

MediWound Reports First Quarter 2026 Financial Results and Provides Corporate Update

Newly Published U.S. Expert Consensus Aligns with MediWound's Strategy for Chronic Wound Debridement

MediWound Reports BARDA Contract Award to Vericel for NexoBrid® Valued at up to $197 Million

MediWound Files Annual Report on Form 20-F

MediWound Ltd. (MDWD) Q1 2026 Earnings Call Transcript

MediWound Q1 Earnings Call Highlights

MediWound (MDWD) Reports Q1 Loss, Misses Revenue Estimates

MediWound Reports First Quarter 2026 Financial Results and Provides Corporate Update

MediWound to Report First Quarter 2026 Financial Results

Newly Published U.S. Expert Consensus Aligns with MediWound's Strategy for Chronic Wound Debridement

MediWound to Present New EscharEx® Data at Leading Wound Care Conferences

Videos

No Data

Press releases

MediWound Reports First Quarter 2026 Financial Results and Provides Corporate Update

Newly Published U.S. Expert Consensus Aligns with MediWound's Strategy for Chronic Wound Debridement

MediWound Reports BARDA Contract Award to Vericel for NexoBrid® Valued at up to $197 Million

MediWound Files Annual Report on Form 20-F

Search stocks

MediWound Ltd. (MDWD)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

MediWound Ltd. (MDWD)

MediWound Ltd. (MDWD) Q1 2026 Earnings Call Transcript

MediWound Q1 Earnings Call Highlights

MediWound (MDWD) Reports Q1 Loss, Misses Revenue Estimates

MediWound Reports First Quarter 2026 Financial Results and Provides Corporate Update

MediWound to Report First Quarter 2026 Financial Results

Newly Published U.S. Expert Consensus Aligns with MediWound's Strategy for Chronic Wound Debridement

MediWound to Present New EscharEx® Data at Leading Wound Care Conferences

Videos

No Data

Press releases

MediWound Reports First Quarter 2026 Financial Results and Provides Corporate Update

Newly Published U.S. Expert Consensus Aligns with MediWound's Strategy for Chronic Wound Debridement

MediWound Reports BARDA Contract Award to Vericel for NexoBrid® Valued at up to $197 Million

MediWound Files Annual Report on Form 20-F

MediWound Ltd. (MDWD) Q1 2026 Earnings Call Transcript

MediWound Q1 Earnings Call Highlights

MediWound (MDWD) Reports Q1 Loss, Misses Revenue Estimates

MediWound Reports First Quarter 2026 Financial Results and Provides Corporate Update

MediWound to Report First Quarter 2026 Financial Results

Newly Published U.S. Expert Consensus Aligns with MediWound's Strategy for Chronic Wound Debridement

MediWound to Present New EscharEx® Data at Leading Wound Care Conferences

Videos

No Data

Press releases

MediWound Reports First Quarter 2026 Financial Results and Provides Corporate Update

Newly Published U.S. Expert Consensus Aligns with MediWound's Strategy for Chronic Wound Debridement

MediWound Reports BARDA Contract Award to Vericel for NexoBrid® Valued at up to $197 Million

MediWound Files Annual Report on Form 20-F